Capital Investment Counsel Inc Buys 89 Shares of Eli Lilly and Company $LLY

Capital Investment Counsel Inc grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 771 shares of the company’s stock after purchasing an additional 89 shares during the period. Capital Investment Counsel Inc’s holdings in Eli Lilly and Company were worth $601,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the second quarter valued at $35,000. TD Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Finally, Family CFO Inc bought a new stake in Eli Lilly and Company in the second quarter worth $54,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $1,018.28 on Thursday. The business has a fifty day moving average of $815.33 and a 200 day moving average of $778.16. The stock has a market cap of $962.67 billion, a P/E ratio of 66.55, a PEG ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,022.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Wall Street Analysts Forecast Growth

Several research firms have commented on LLY. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $886.00 to $1,104.00 in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $981.89.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.